Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Cefazolin plus amikacin vs vancomycin plus amikacin

All‐cause mortality maximum · newborns with late‐onset sepsis

It is very uncertain whether cefazolin plus amikacin changes all‐cause mortality maximum compared with vancomycin plus amikacin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.7 [0.29, 1.66]
1 study · 109 participants
Very low

Cefazolin plus amikacin vs vancomycin plus amikacin

Serious adverse events maximum · newborns with late‐onset sepsis

It is very uncertain whether cefazolin plus amikacin changes serious adverse events maximum compared with vancomycin plus amikacin (very low certainty).

1 finding from 1 review

Antibiotic regimens for late‐onset neonatal sepsis 2021 · Cochrane Headline outcomes only
RR 0.7 [0.29, 1.66]
1 study · 109 participants
Very low